Company Overview - 23andMe, a genetic testing company founded in 2006, initially gained consumer interest with ancestry-focused genetic testing kits and later expanded to health risk assessments in 2017 [2] - The company went public in June 2021 at $11.13 per share and acquired virtual care startup Lemonaid Health for $400 million in cash and stock later that year [3][4] - 23andMe's valuation has significantly declined from $3.5 billion at IPO to approximately $91 million as of January 2024 [4] Financial and Operational Challenges - The company's stock price has plummeted due to a 2023 data breach affecting nearly 7 million users, leading to a $30 million class action lawsuit settlement [3][5][6] - In response to financial struggles, 23andMe cut 40% of its workforce (approximately 200 employees) in November 2023 and discontinued its drug discovery efforts [3] - To avoid delisting from Nasdaq, the company executed a reverse stock split in October 2023, exchanging every 20 shares for one share [4] Strategic Developments - 23andMe is exploring the potential sale of its telehealth business, Lemonaid Health, which it acquired in 2021 [1][9] - CEO Anne Wojcicki proposed taking the company private in July 2024, but the bid was rejected by a special committee of the board of directors [7] - Following the rejection, Wojcicki expressed openness to a third-party takeover in September 2024, but later retracted the statement, reaffirming her intention to take the company private [7][8] Data Breach Impact - The 2023 data breach exposed sensitive user information, including names and birth details, which were subsequently sold on the dark web [5] - The company took five months to detect the breach, leading to significant reputational damage and legal consequences [6]

Company Overview - ImmunityBio Inc (NASDAQ: IBRX) is a biotech company that has been subject to fluctuating market valuations, with concerns raised about the level of execution risk priced into its valuation [1] Analyst Background - The analyst holds a PhD in biochemistry and has extensive experience in analyzing clinical trials and biotech companies [1] - The analyst aims to educate investors on the science behind biotech investments and help them conduct thorough due diligence to avoid potential pitfalls [1] Disclosure - The analyst has no stock, option, or derivative positions in any of the mentioned companies and no plans to initiate such positions within the next 72 hours [2] - The article represents the analyst's personal opinions and is not influenced by any compensation or business relationships with the mentioned companies [2]

SAVA Announcement: Kessler Topaz Meltzer & Check, LLP Encourages Cassava Sciences, Inc. (SAVA) Investors to Contact the Firm About Securities Fraud Class Action Lawsuit ...

EnglishItalianoEspañolPortuguêsDeutschالعربيةFrançaisImportant DisclaimersThe content provided on the website includes general news and publications, our personal analysis and opinions, and contents provided by third parties, which are intended for educational and research purposes only. It does not constitute, and should not be read as, any recommendation or advice to take any action whatsoever, including to make any investment or buy any product. When making any financial decision, you should perform your ...

Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of February 3, 2025 in Five9, Inc. Lawsuit - FIVN ...

U.S. stocks traded higher toward the end of trading, with the S&P 500 gaining around 1% on Friday.The Dow traded up 0.99% to 43,580.17 while the NASDAQ rose 1.81% to 19,688.08. The S&P 500 also rose, gaining, 1.25% to 6,011.81.Check This Out: Top 3 Defensive Stocks That Could Blast Off This QuarterLeading and Lagging SectorsConsumer discretionary shares surged by 2.3% on Friday.In trading on Friday, health care shares fell by 0.1%.Top HeadlineState Street Corporation STT posted better-than-expected fourth-q ...

Growth stocks are attractive to many investors, as above-average financial growth helps these stocks easily grab the market's attention and produce exceptional returns. However, it isn't easy to find a great growth stock.By their very nature, these stocks carry above-average risk and volatility. Moreover, if a company's growth story is over or nearing its end, betting on it could lead to significant loss.However, it's pretty easy to find cutting-edge growth stocks with the help of the Zacks Growth Style Sco ...

Growth investors focus on stocks that are seeing above-average financial growth, as this feature helps these securities garner the market's attention and deliver solid returns. But finding a great growth stock is not easy at all.That's because, these stocks usually carry above-average risk and volatility. In fact, betting on a stock for which the growth story is actually over or nearing its end could lead to significant loss.However, the task of finding cutting-edge growth stocks is made easy with the help ...

Shareholders that lost money on Edison International (EIX) should contact Levi & Korsinsky about Securities Fraud Investigation - EIX ...

This account is managed by Noah's Arc Capital Management. Our goal is provide Wall Street level insights to main street investors. Our research focus is mainly on 20th century stocks (old economy) undergoing a 21st century transformation, but occasionally we'll write on companies that help transform 20th century firms as well. We look for innovations in a business model that will cause a stock to change dramatically. Associated with SA contributors Thomas Potter and Elijah Buell.Analyst’s Disclosure: I/we h ...